Dennis J. Slamon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dennis J. Slamon has a total of 681 co-authors. Here are the top co-authors by number of shared publications:
- Martina S.J. McDermott
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
105 shared publications - Neil A. O'BRien
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
102 shared publications - John A. Glaspy
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
97 shared publications - Benjamin Hoffstrom
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - Jun Zhang
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - KeWei Gong
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Topoisomerase-Based CDH17 Antibody–Drug Conjugates Overcome P-gp Resistance but Undergo Target-Mediated Clearance in Colorectal Cancer
Purpose: Cadherin 17 (CDH17) is an emerging therapeutic target in colorectal cancer; however, the effects of drug efflux and physiologic CDH17 expression on the activity and pharmacokinetics (PK) of CDH17-directed antibody–drug conjugates (ADC) remain poorly understood. We evaluated the impact of payload selection and target-mediated clearance on CDH17-directed ADCs. Experimental Design: CDH17-directed ADCs carrying either monomethyl auristatin E (MMAE) or the topoisomerase 1 inhibitor exatecan were evaluated in colorectal cancer models with variable P-glycoprotein (P-gp) expression. The effects of P-gp modulation on ADC sensitivity were assessed. CDH17 expression in human tissues was characterized by immunohistochemistry (IHC), and PK studies were performed in cynomolgus monkeys and mice engineered to express human CDH17. Results: CDH17-exatecan ADCs demonstrated greater antitumor activity than CDH17-MMAE ADCs in P-gp–expressing colorectal cancer models. Forced P-gp expression induced resistance to CDH17–MMAE ADCs without affecting sensitivity to CDH17-exatecan ADCs, whereas genetic or pharmacologic inhibition of P-gp restored CDH17–MMAE activity. CDH17 was highly expressed in colorectal cancer and localized to the lateral membranes of gastrointestinal (GI) epithelial cells in normal tissues. In mice expressing human CDH17, CDH17-directed antibodies and ADCs exhibited approximately fourfold faster clearance than in wild-type (WT) mice or cynomolgus monkeys, consistent with substantial target-mediated systemic drug clearance. Conclusions: Together, these findings identify topoisomerase 1 inhibitor payloads, such as exatecan, as advantageous for targeting P-gp–expressing colorectal cancers while highlighting target-mediated clearance and potential on-target, off-tumor toxicity as important translational challenges for CDH17-directed therapeutics and other ADCs targeting antigens with substantial normal tissue expression.
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Open AccessTopoisomerase-Based CDH17 Antibody–Drug Conjugates Overcome P-gp Resistance but Undergo Target-Mediated Clearance in Colorectal Cancer
Purpose: Cadherin 17 (CDH17) is an emerging therapeutic target in colorectal cancer; however, the effects of drug efflux and physiologic CDH17 expression on the activity and pharmacokinetics (PK) of CDH17-directed antibody–drug conjugates (ADC) remain poorly understood. We evaluated the impact of payload selection and target-mediated clearance on CDH17-directed ADCs. Experimental Design: CDH17-directed ADCs carrying either monomethyl auristatin E (MMAE) or the topoisomerase 1 inhibitor exatecan were evaluated in colorectal cancer models with variable P-glycoprotein (P-gp) expression. The effects of P-gp modulation on ADC sensitivity were assessed. CDH17 expression in human tissues was characterized by immunohistochemistry (IHC), and PK studies were performed in cynomolgus monkeys and mice engineered to express human CDH17. Results: CDH17-exatecan ADCs demonstrated greater antitumor activity than CDH17-MMAE ADCs in P-gp–expressing colorectal cancer models. Forced P-gp expression induced resistance to CDH17–MMAE ADCs without affecting sensitivity to CDH17-exatecan ADCs, whereas genetic or pharmacologic inhibition of P-gp restored CDH17–MMAE activity. CDH17 was highly expressed in colorectal cancer and localized to the lateral membranes of gastrointestinal (GI) epithelial cells in normal tissues. In mice expressing human CDH17, CDH17-directed antibodies and ADCs exhibited approximately fourfold faster clearance than in wild-type (WT) mice or cynomolgus monkeys, consistent with substantial target-mediated systemic drug clearance. Conclusions: Together, these findings identify topoisomerase 1 inhibitor payloads, such as exatecan, as advantageous for targeting P-gp–expressing colorectal cancers while highlighting target-mediated clearance and potential on-target, off-tumor toxicity as important translational challenges for CDH17-directed therapeutics and other ADCs targeting antigens with substantial normal tissue expression.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Cell viability assessment in parental BT-474 cells, trastuzumab-resistant BT474 clones (BT-TR1 and BT-TR2) and trastuzumab and pertuzumab-resistant BT474 clones (BT-TPR1 and BT-TPR2) treated with PF-05175157
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Cell viability assessment in parental BT-474 cells, trastuzumab-resistant BT474 clones (BT-TR1 and BT-TR2) and trastuzumab and pertuzumab-resistant BT474 clones (BT-TPR1 and BT-TPR2) treated with PF-05175157
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
ACC1 (ACACA) and ACC2 (ACACB) protein levels in breast cancer cell lines
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
ACC1 (ACACA) and ACC2 (ACACB) protein levels in breast cancer cell lines
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Heatmap of inhibit delta of top 10 drugs across 10 breast cancer cell lines
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Heatmap of inhibit delta of top 10 drugs across 10 breast cancer cell lines
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File S1 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Results of a high-throughput cell proliferation screen of 385 human cancer cell lines treated with PF-05175157, identifying sensitive multiple myeloma, breast, ovarian, and lung cancer cell lines.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S1 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Results of a high-throughput cell proliferation screen of 385 human cancer cell lines treated with PF-05175157, identifying sensitive multiple myeloma, breast, ovarian, and lung cancer cell lines.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Cell lines with IC50 concentrations below 10 mmol/L threshold that was readily achievable in human serum, in Phase I/II clinical trials with PF-05175157
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Cell lines with IC50 concentrations below 10 mmol/L threshold that was readily achievable in human serum, in Phase I/II clinical trials with PF-05175157
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File S4 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Significantly upregulated genes associated with metabolic repair and recovery pathways identified following PF-05175157 treatment.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S4 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Significantly upregulated genes associated with metabolic repair and recovery pathways identified following PF-05175157 treatment.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File S3 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Lipidomic results: PF-05175157 effect on cellular lipid composition
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S3 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
Lipidomic results: PF-05175157 effect on cellular lipid composition
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
MRNA expression levels endoplasmic reticulum stress related genes at baseline and after 24 hours exposure to PF-05175157 in MDA-MB-468 cells
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Inhibition of Acetyl-CoA Carboxylase Induces Endoplasmic Reticulum Stress and Augments the Efficacy of Anticancer Therapies
MRNA expression levels endoplasmic reticulum stress related genes at baseline and after 24 hours exposure to PF-05175157 in MDA-MB-468 cells